



1633

Dkt. 0575/62096/JPW/JML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David M. Stern, et al.

U.S. Serial No.: 09/687,528

Filed : October 13, 2000

For : A METHOD FOR INHIBITING NEW TISSUE GROWTH IN
BLOOD VESSELS IN A PATIENT SUBJECTED TO BLOOD
VESSEL INJURY

RECEIVED

JUL 18 2001

TECH CENTER 1600/2900

1185 Avenue of the Americas
New York, New York 10036
July 13, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED

JUL 18 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents, which are listed hereinbelow and again listed on Form PTO-1449 attached hereto as **Exhibit A**. Copies of the documents listed below are attached hereto as **Exhibits 1-16**.

1. **U.S. Patent No. 5,879,380**, issued March 9, 1999 to Kalmann, et al., Assembly For Treating Blood Vessels And A Method Therefor.
2. **U.S. Patent No. 5,843,102**, issued December 1, 1998, to Kalmann, et al., Instrument For Loosening And Cutting Through The Intima Of A Blood Vessel And A Method Therefor.

David M. Stern, et al.
U.S. Serial No.: 09/687,528
Filed: October 13, 2000
Page 2

3. U.S. Patent 6,071,514, issued June 6, 2000 to Grinell, et al., Methods For Treating Thrombotic Disorders.
4. Morser et al., U.S. Patent No. 5,864,018, filing date April 16, 1996.
5. Morser et al. PCT International Application No. PCT/EP97/01834, filed April 11, 1997, published October 23, 1997; Publication No. WO 97/39125, Antibodies Against the Advanced Glycation Endproduct Receptor and Uses Thereof.
6. Morser et al. PCT International Application No. PCT/EP97/01832, filed 11 April 1997, published October 23, 1997, Publication No. WO 97/39121, Advanced Glycation Endproduct Receptor Peptides and Uses Thereof.
7. Stern et al., PCT International Publication No. WO 97/26913, published July 31, 1997, PCT International Application No. PCT/US97/00857 (Attney Dkt 48316-PCT).
8. Stern, D., AM Schmidt and Jun Wu - A Method For Treating Symptoms Of Diabetes In A Subject (PCT International Publication No. PCT/US97/21197, filed November 12, 1997) (Attney Dkt. 50159-PCT).

9. Stern, D., Shi Du Yan, Ann Marie Schmidt - **PCT International Application No. PCT/US98/21346**; filed 09 OCT 98; Ligand Binding Site of RAGE, (Attney Dkt. 53447-PCT).
10. Hoffman, M.A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., Neurath, M.F., Slattery, T., Beach, D., McClary, J., Nagashima, M., Morser, J., Stern, D., and Schmidt, A.M. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. *Cell* 97:889-901.
11. Lander, H.L., Tauras, J.M., Ogiste, J.S., Moss, R.A., and A.M. Schmidt. (1997) Activation of the Receptor for Advanced Glycation Endproducts triggers a MAP Kinase pathway regulated by oxidant stress. *J. Biol. Chem.* 272:17810-17814.
12. Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. *J. Biol. Chem.* 267: 14998-15004.
13. Park, L., Raman, K.G., Lee, K.J., Yan, L., Ferran, L.J., Chow, W.S., Stern, D., and Schmidt, A.M. (1998) Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE). *Nature Medicine* 4:1025-1031.
14. Schmidt, A-M, et al. (1992) "Isolation and characterization of

binding proteins for advanced glycation endproducts from lung tissue which are present on the endothelial cell surface" *J. Biol. Chem.*, 267:14987-14997.

15. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Gostache G, Simionescu N, Simionescu M, Stern D. (1994) Receptor for advanced glycation end products (AGE) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. *Proc Natl Acad Sci USA* 91:8807-11.
16. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. *Nat. Med.* 643-51.

Applicants request the Examiner make these references of record.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone at the number provided below.

David M. Stern, et al.
U.S. Serial No.: 09/687,528
Filed: October 13, 2000
Page 5

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. If any additional fees are required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Jane M. Love

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
<i>Jane M. Love</i>	<i>7/13/01</i>
John P. White	Date
Reg. No. 28,678	
Jane M. Love	
Reg. No. 42,812	

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400